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ABSTRACT
Purpose: To compare visual outcomes and
treatment burden between intravitreally
administered aflibercept (IVT-AFL) and ranibi-
zumab (RBZ) treat-and-extend (T&E) regimens
in patients with wet age-related macular
degeneration (wAMD) at 2 years.
Methods: A systematic literature review was
carried out in Medline, EMBASE, and CENTRAL
in October 2018. Matching-adjusted indirect
comparison (MAIC) and/or individual patient
data meta-regression was used to connect
ALTAIR (assessing IVT-AFL T&E) with other
studies, adjusting for between-trial differences
in baseline visual acuity and age or baseline
visual acuity, age, and polypoidal choroidal
vasculopathy (PCV) status. Sensitivity analyses
were conducted to test the robustness of the
results, including direct MAIC between IVT-AFL
T&E (ALTAIR) and RBZ T&E (CANTREAT and
TREX-AMD trials).
Results: Six randomized controlled trials
(RCTs) (ALTAIR, VIEW 1 and 2, CATT, CAN-
TREAT, and TREX) were included in the analy-
sis. IVT-AFL T&E was assessed in one study,
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ALTAIR (n = 255), while RBZ T&E was assessed
in two trials (n = 327). At 2 years, the median
difference (95% credibility interval) between
IVT-AFL T&E and RBZ T&E regarding the num-
bers of Early Treatment Diabetic Retinopathy
Study (ETDRS) letters gained was not significant
(M1: - 2.29 [- 8.10, 3.58]; M2: - 0.55 [- 6.34,
5.29]). IVT-AFL T&E was associated with signif-
icantly fewer injections than RBZ-T&E (M1:
- 6.12 [- 7.60, - 4.65]; M2: - 5.93 [- 7.42,
- 4.45]). Results of the sensitivity analyses were
consistent with the main scenarios.
Conclusion: Patients with wAMD receiving an
IVT-AFL T&E regimen achieved and maintained
improvement in visual acuity with fewer injec-
tions over 2 years compared with RBZ T&E. IVT-
AFL T&E may therefore serve as the optimal
therapy for wAMD, as it was associated with
clinical efficacy and minimized treatment
burden.
Keywords: Intravitreal anti-vascular endothe-
lial growth factor therapy; Network meta-
analysis; Ophthalmology; Wet age-related
macular degeneration
Key Summary Points
Why carry out this study?
The goal of anti-vascular endothelial
growth factor (VEGF) treatment for wet
age-related macular degeneration (wAMD)
beyond the first 12 months is to maintain
or improve functional and anatomic gains
achieved during the 1st year of treatment,
while minimizing the burden on patients
related to clinical visits and the number of
injections.
Independently, both intravitreally
administered aflibercept (IVT-AFL) treat-
and-extend (T&E) and ranibizumab (RBZ)
T&E regimens have demonstrated a
reduced treatment burden compared with
bimonthly and monthly traditional anti-
VEGF regimens, while maintaining
efficacy in visual acuity (VA) gains in a
long-term perspective (e.g., 2 years).
Randomized controlled trials (RCTs)
describe outcomes with IVT-AFL T&E and
RBZ T&E at 1 year; however, head-to-head
data on IVT-AFL T&E and RBZ T&E
regimens showing the long-term
perspective (2 years) is limited.
In this analysis, we completed an indirect
treatment comparison/network meta-
analysis to compare IVT-AFL T&E versus
RBZ T&E at 2 years regarding visual
outcomes (mean change in Early
Treatment Diabetic Retinopathy Study
[ETDRS] letters vs baseline) and treatment
burden (mean number of injections).
What was learned from the study?
The analysis indicates that in a clinical
trial setting both IVT-AFL T&E and RBZ
T&E are efficacious in the treatment of
patients with wAMD. Both regimens are
associated with comparable efficacy
regarding number of ETDRS letters gained
vs baseline after 2 years.
When assessing the associated treatment
burden, patients receiving IVT-AFL T&E
can achieve these outcomes with fewer
injections. At 2 years, IVT-AFL T&E was
associated with, on average, six fewer
injections than RBZ T&E.
The high between-treatment difference in
the number of injections is consistent
with individual RCT results and reflects
differences in the T&E regimens tested as
well as the criteria for extension adopted
in the studies included in the analysis.
On the basis of in the evidence assessed,
IVT-AFL T&E may serve as optimal
therapy for wAMD vs RBZ T&E, as it is
associated with similar clinical efficacy
and reduced treatment burden over the
first 2 years of treatment.
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INTRODUCTION
Age-related macular degeneration affects 8.7%
of the adult population globally [1] and is a
leading cause of visual impairment and severe
vision loss worldwide [2]. Neovascular (wet)
age-related macular degeneration (wAMD) is a
chronic and progressive degenerative disorder
that is characterized by the presence of neo-
vascularization within the macula and leads to
severe vision impairment or loss of vision in
older patients [3].
There is no curative treatment for wAMD;
however, the progression of visual impairment
can be slowed down or reversed to some extent
with anti-vascular endothelial growth factor
(anti-VEGF) therapies [4]. The inhibition of
VEGF prevents neovascularization, decreases
capillary leakage, and has proven efficacy in
restoring visual acuity [4, 5]. Two anti-VEGF
therapies have been approved and are currently
in use globally for the treatment of wAMD:
ranibizumab treat-and-extend (RBZ T&E;
Lucentis; Novartis Pharma AG, Basel, Switzer-
land) and aflibercept treat-and-extend (IVT-AFL
T&E; Eylea; Bayer Consumer Care AG, Basel,
Switzerland for use outside of the USA). Both
therapies are administered as intravitreal injec-
tions based on regimens with fixed or flexible
intervals between administrations.
Although anti-VEGF therapy has become the
mainstay in the treatment of wAMD, the need
for repeated intravitreal injections imposes a
serious burden on patients due to treatment-
related anxiety, financial considerations, and
transport burden [6]. Two strategies allowing for
flexibility in the frequency of anti-VEGF
administration have been developed. Under a
pro re nata (PRN) regimen, the decision
regarding whether to give an anti-VEGF injec-
tion is made at each visit, based on the results of
an optical coherence tomography. Conversely,
with treat-and-extent (T&E) regimens, a proac-
tive treatment approach is taken; the patient
receives an intravitreal injection at every visit,
but intervals between consecutive visits can be
adjusted on the basis of disease progression.
Intravitreal administration of anti-VEGF agents
may be carried out only by qualified personnel
and requires highly specialized diagnostic pro-
cedures, making the therapy burdensome also
for healthcare systems [7]. For this reason, an
optimal treatment strategy will allow uncom-
promised clinical effectiveness with a reduced
treatment burden.
In theory, the PRN regimen requires the
same number of visits as for the fixed-interval
regimen, although patients may receive injec-
tions less frequently compared with fixed
monthly interval dosing; however, in daily
practice PRN is associated with suboptimal effi-
cacy, possibly driven by undertreatment of the
disease [8]. It has been observed that patients
who were switched from a PRN to a T&E regi-
men experienced improvement in visual acuity
even 8 years after initial treatment [8, 9]. The
switch to T&E was associated with a reduced
number of visits and a slightly higher number of
injections [9]. Therefore, T&E regimens are
considered to be optimal strategies for intravit-
real anti-VEGF administration, yielding nonin-
ferior efficacy and a noticeably decreased
treatment-related burden compared with a
fixed-interval posology [10–13].
Good treatment adherence has been recog-
nized as another factor associated with optimal
visual acuity in patients with wAMD treated
with anti-VEGF therapy [14]. In the reality of
clinical practice, missed visits or even treatment
terminations are more frequent when the
patient requires a higher frequency of visits
[15, 16].
The publicly available evidence describes
efficacy and treatment burden associated with
IVT-AFL T&E and RBZ T&E, but there are lim-
ited data that could be used to assess the relative
efficacy and treatment burden of both drugs. A
recently published RIVAL trial did not demon-
strate differences between IVT-AFL and RBZ
regarding visual outcomes and the mean num-
ber of injections at 1 and 2 years [17, 18]. The
authors describe that all patients received
assigned treatment according to T&E regimen,
although the frequency of injections in the AFL
arm was higher compared with a fixed 8-week
regimen. Thus, in the light of concerns regard-
ing external validity of the RIVAL study, the
question and credibility of presented estimates
remains. Therefore, we attempted to compare
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both regimens using validated methods for
indirect treatment comparison (ITC), including
individual patient data (IPD) meta-regression
and matching-adjusted indirect treatment
comparison (MAIC) to establish the connection
in the network of evidence for a network meta-
analysis (NMA).
METHODS
This NMA was preceded by a systematic litera-
ture review (SLR) of randomized controlled tri-
als (RCTs) assessing efficacy and treatment
burden of anti-VEGF therapies administered in
patients with wAMD according to the approved
posology [19].
In the SLR, the following inclusion criteria
were used: at least 40 patients with wAMD,
assessment of visual outcomes and/or treatment
burden followed up for at least 2 years, and a
comparison between at least two of the follow-
ing regimens: IVT-AFL T&E or IVT-AFL every
8 weeks (Q8W), and RBZ T&E or RBZ every
4 weeks (Q4W), and IVT-AFL or RBZ adminis-
tered PRN. Studies with a follow-up shorter than
2 years, those using an off-label dosage of IVT-
AFL or RBZ or using off-label therapies, and
those without relevant outcomes were exclu-
ded. The search was conducted according to the
guidelines of the Cochrane Collaboration [20]
and PRISMA statement [21] and was based on
the keywords related to wAMD, assessed inter-
ventions, and RCTs combined with appropriate
Boolean operators. The Medline and EMBASE
databases (access via Ovid platform),
Cochrane’s CENTRAL database, conference
websites, and clinical trial registries were sear-
ched up to October 4, 2018, with no restrictions
on language and geographical scope (the search
strategy is presented in Tables 1 and 2 in the
supplementary material). Studies were selected
by two independent reviewers with differences
resolved by a third reviewer. Data were extrac-
ted by one analyst and quality control was
performed by another analyst. The Cochrane
risk of bias tool checklist was used to assess the
quality of the included studies. This study is a
secondary analysis based on the results of data
collected within eligible clinical trials. The data
source included aggregated, clinical results
identified from the public domain as well as
limited individual patients’ data from ALTAIR
and VIEW 1 & 2 trials. Individual patient data
were anonymized before sharing, so that the
analysts had no access to any personal infor-
mation allowing one to identify individual
patients. For this reason, this study did not
require any ethical approval.
Indirect Treatment Comparison
for Disconnected Studies
An NMA has been recommended to compare
treatments assessed in studies which form a
connected network of evidence [22]. The com-
parison of interventions assessed in discon-
nected studies requires careful adjustment for
baseline differences that could bias the estima-
tion of the relative effect. In this analysis,
treatments from disconnected studies were
compared, accounting for the differences in the
baseline characteristics using methodologies
recommended by the Decision Support Unit
commissioned by the National Institute for
Health and Care Excellence (NICE DSU),
including the MAIC and regression analysis
[23, 24]. Both methods require the use of
patient-level data to calculate the difference
between outcomes observed in disconnected
arms, adjusting for differences in distributions
of baseline characteristics with a potential to
modify the treatment effects, referred to as
treatment confounders. According to the
guidelines, the comparison was carried out
between studies on similar populations, which
reduces the loss of information and risk of bias
[23].
Individual Patient Data Meta-Regression
Analysis
The IPD meta-regression analysis included IPD
from disconnected studies and adopted multi-
ple linear regression analysis to estimate the
difference between disconnected arms. The
difference between disconnected regimens was
assessed adjusting for the baseline age (age0)
and the baseline best-corrected visual acuity
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(BCVA0) expressed with the Early Treatment
Diabetic Retinopathy Study (ETDRS) letters. The
outcomes of interest [change in best-corrected
visual acuity (BCVA): dBCVA1y, and the total
number of injections at 1 year: No inj1y] were
considered as dependent variables, while the
assigned treatment (trt) and baseline character-
istics were analyzed as independent variables, as
presented in the equations below:
dBCVA1y ¼ a0 þ a1trt þ a2BCVA0 þ a3age0
No inj1y ¼ a0 þ a1trt þ a2BCVA0 þ a3age0
Regression coefficients a0; a1; a2; and a3
represent intercept, adjusted between-
treatment difference, contribution of baseline
BCVA, and age, respectively.
Matching-Adjusted Indirect Treatment
Comparison
MAIC requires access to patient-level data from
one trial, which are matched in terms of base-
line characteristics with aggregated data from
the other study using propensity score match-
ing technique as described by NICE DSU Tech-
nical Support Document 18 [22]. Weights
calculated during the matching and effects
observed for each individual patient were used
to recalculate the adjusted effect in the treat-
ment group. The standard error for the adjusted
effect was estimated using the nonparametric
bootstrap method described by Gatz and Smith
[25]. The adjusted effects were then compared
with pooled estimates from the disconnected
comparator group using the traditional statisti-
cal methodology for a comparison of two pop-
ulation means. The baseline characteristics used
for matching included age, BCVA, and poly-
poidal choroidal vasculopathy (PCV).
An effective sample size (ESS) was calculated
and reported for each analysis according to the
recommendations of the NICE DSU [23, 24].
Analyses for which the ESS was reduced by more
than 50% in comparison with the available IPD
were not considered reliable owing to a high
risk of bias and were not presented in this paper.
Network Meta-Analysis
An NMA in a Bayesian framework was con-
ducted to compare the IVT-AFL T&E regimen
with the RBZ T&E regimen as outlined in the
NICE DSU Technical Support Document [22].
Estimates from ITC (meta-regression or MAIC)
were incorporated in the network of evidence
with the results from RCTs. The NMA was con-
ducted on the mean between-treatment differ-
ences for BCVA gain from baseline and the
mean differences in the number of intravitreal
injections at 2 years using both random- and
fixed-effects models. The selection of the model
was based on the value of the deviance infor-
mation criterion (DIC). Results were reported as
the median between-treatment differences
together with 95% credibility intervals (CrI).
Missing standard deviations (SD) were imputed
with the SD associated with the same treat-
ments in other included studies. Analyses were




The SLR identified 3134 potentially relevant
citations, out of which eight (six RCTs) were
included in the analysis (a PRISMA diagram is
presented in Fig. 1 in the supplementary mate-
rial). The six RCTs compared approved regimens
of IVT-AFL and/or RBZ at 2 years in terms of the
BCVA gain from baseline and the number of
injections (ALTAIR [26], VIEW 1 and 2 [27],
CATT [28], CANTREAT [12], and TREX [13]).
IVT-AFL T&E was assessed in one study [26],
including a total of 255 patients, while RBZ T&E
was assessed in two studies [12, 13], including a
total of 327 patients. The mean age at baseline
ranged from 73.0 (IVT-AFL T&E 2-week adjust-
ment) to 75.0 (IVT-AFL T&E 4-week adjustment)
in the ALTAIR trial and from 76.0 (TREX) to
78.8 (CANTREAT) in trials assessing RBZ T&E.
The mean BCVA at baseline ranged from 54.8
(IVT-AFL T&E 2-week adjustment) to 55.3 (IVT-
AFL T&E 4-week adjustment) in the ALTAIR trial
and from 58.7 (CANTREAT) to 59.9 (TREX) in
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trials assessing RBZ T&E. At 2 years, the mean
BCVA gain from baseline was 6.1 (IVT-AFL T&E
4-week adjustment) and 7.6 (IVT-AFL T&E
2-week adjustment) ETDRS letters in IVT-AFL
T&E with 4- and 2-week adjustment arms,
respectively, while the visual acuity of patients
treated with RBZ T&E improved by 6.4 and 8.7
letters in the CANTREAT and TREX trials,
respectively. At 2 years, patients in both ALTAIR
arms received 10.4 injections on average, while
their counterparts from the CANTREAT and
TREX trials were administered 18 and 18.6
injections (Table 1).
Evidence Network
The only RCT on IVT-AFL T&E (ALTAIR,
NCT02305238) was designed to compare two
IVT-AFL T&E regimens using 2-week and 4-week
adjustments. After four initial doses adminis-
tered at weeks 0, 4, 8, and 16, IVT-AFL T&E was
injected at variable treatment intervals ranging
from 8 to 16 weeks. The ALTAIR trial was dis-
connected from the network of other studies.
Therefore, the connection between the ALTAIR
study and the network of evidence accounting
for the differences in the baseline characteristics
had to be established in order to allow for
quantitative comparison between IVT-AFL T&E
and RBZ T&E. The comparison was considered
the most appropriate between the ALTAIR and
combined data from VIEW 1 and 2 trials, as the
distributions of both BCVA and age at baseline
and access to patient-level data were similar.
Two methods dedicated to comparing
Table 1 Baseline characteristics of populations from identified RCTs included in the ITC











ALTAIR [26] IVT-AFL T&E (2-weeks adj) 124 54.8 (13.1) 73.0 (7.9) 38.0
ALTAIR [26] IVT-AFL T&E (4-weeks adj) 123 55.3 (12.0) 75.0 (8.1) 37.9
VIEW 1 [27] IVT-AFL Q8 ? PRN 301 55.7 (12.8) 77.9 (8.4) 12.0a
VIEW 1 [27] RBZ Q4 ? PRN 304 54.0 (13.4) 78.2 (7.6)
VIEW 2 [27] IVT-AFL Q8 ? PRN 306 51.6 (13.9) 73.8 (8.6)
VIEW 2 [27] RBZ Q4 ? PRN 291 53.8 (13.5) 73.0 (9.0)
TREX-AMD [13] RBZ T&E 40 59.9 (14.2) 76.0 (n/a) 8.7a
TREX-AMD [13] RBZ Q4 20 60.3 (10.7) 79.0 (n/a)
CANTREAT [12] RBZ T&E 287 58.7 (14.2) 58.7 (14.2) 8.7a
CANTREAT [12] RBZ Q4 293 59.4 (13.5) 59.4 (13.5)
CATT [28] RBZ Q4 146 59.9 (14.2) 79.5 (7.4) Not assessed
CATT [28] RBZ Q4 ? PRN 138 60.9 (14.3) 78.8 (7.5) Not assessed
BCVA best-corrected visual acuity, IVT-AFL intravitreally administered aflibercept, PCV polypoidal choroidal vasculopa-
thy, Q4 one injection every 4 weeks, Q4 ? PRN one injection every 4 weeks in the first year followed by pro re nata
regimen in the second year, Q8 ? PRN one injection every 8 weeks in the first year followed by pro re nata regimen in the
second year, RBZ ranibizumab, SD standard deviation, T&E treat-and-extend regimen, 2-wk adj treatment interval adjusted
every 2 weeks, 4-wk adj treatment interval adjusted every 4 weeks
a Values estimated
Adv Ther (2020) 37:2184–2198 2189
disconnected evidence were tested as described
in the ‘‘Methods’’ (Fig. 1).
In the main analysis 1 (M1), the meta-re-
gression analysis on IPD was conducted to
assess the difference between the ALTAIR study
(2-week adjustment) versus IVT-AFL Q8W/PRN
in VIEW 1 and 2, adjusting for the baseline age
and the baseline BCVA. A sensitivity analysis
was conducted pooling both arms of the
ALTAIR trial (2-week adjustment and 4-week
adjustment), with patients receiving the IVT-
AFL Q8W/PRN regimen using the same IPD
meta-regression techniques.
MAIC was used as the second method to
anchor the ALTAIR trial to the network of evi-
dence through the VIEW trials. In the main
analysis 2 (M2), the weights were assigned to
patients receiving IVT-AFL T&E (2-week adjust-
ment) in the ALTAIR trial to balance the dif-
ferences in the baseline characteristics of
patients treated with IVT-AFL Q8W/PRN in the
VIEW 1 and 2 studies. The baseline characteris-
tics used for matching included age, BCVA, and
PCV. Because PCV status was not reported in
VIEW trials, it was estimated assuming the same
PCV prevalence as in the ALTAIR trial (38%) for
the subset of Asian patients and as reported by
Lorentzen et al. [29] for those with non-Asian
ethnicity (8.75%). On the basis of these
assumptions, the overall prevalence of patients
with PCV in the VIEW trials was 12%. Several
sensitivity analyses were conducted to test the
robustness of the results, including matching of
IPD from the VIEW studies to adjust for aggre-
gated baseline characteristics from the ALTAIR
study, comparison with different IVT-AFL T&E
regimens (2-week, 4-week, 2- and 4-week regi-
mens), as well as comparison between the IVT-
AFL T&E (ALTAIR) and RBZ T&E regimen
(CANTREAT and TREX-AMD). Although the
sample of the ALTAIR trial was limited, the
baseline characteristics were well matched in
terms of mean parameter values and corre-
sponding standard deviations. The ESS follow-
ing MAIC did not decrease below 50% of initial
samples of IPD.
Estimates from ITC (meta-regression or
MAIC) were incorporated in the network of
Fig. 1 Network of evidence. Solid lines indicate head-to-
head comparisons within RCTs and a dashed line indicates
a reconstituted connection between studies. BCVA best-
corrected visual acuity, IPD individual patient data, IVT-
AFL intravitreally administered aflibercept, MAIC match-
ing-adjusted indirect comparison, PCV polypoidal chor-
oidal vasculopathy, Q4W one injection every 4 weeks,
Q4W ? PRN one injection every 4 weeks in the first year
followed by pro re nata regimen in the second year,
Q8W ? PRN one injection every 8 weeks in the first year
followed by pro re nata regimen in the second year, RBZ
ranibizumab, T&E treat-and-extend regimen, 2-wk adj
treatment interval adjusted every 2 weeks, 4-wk adj
treatment interval adjusted every 4 weeks
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evidence with the results from RCTs as descri-
bed in the ‘‘Methods’’.
Figure 1 presents the network of evidence
used for NMA, showing head-to-head compar-
isons within RCTs and a reconstituted connec-
tion between studies, with most resembling
distributions of the baseline BCVA and age
(ALTAIR and VIEW). The NMA models with
input data are presented in the supplementary
material.
Results of Indirect Treatment Comparison
of Visual Acuity
The gain in ETDRS letters reported in the
VIEW 1 and 2 and ALTAIR studies at 2 years was
7.6 in both IVT-AFL Q8W/PRN and IVT-AFL
T&E (2-week adjustment) groups. The median
differences (95% CrI) in visual acuity gain
between IVT-AFL Q8W/PRN and IVT-AFL T&E
were 0.73 (- 2.23, 3.69) ETDRS letters for the
IPD meta-regression adjusted for the baseline
BCVA and age (M1) and - 0.99 (- 3.90, 1.93)
ETDRS letters for the MAIC of IVT-AFL T&E
matched to aggregated IVT-AFL Q8W/PRN on
the baseline BCVA, age, and PCV (M2). The
results of all sensitivity analyses were consistent
with M1 and M2 scenarios and did not
demonstrate a significant difference in visual
outcomes between IVT-AFL Q8W/PRN and IVT-
AFL T&E at 2 years.
The NMA pooling results of the network of
RCTs together with the estimated difference
between regimens assessed in the ALTAIR and
VIEW studies did not demonstrate a significant
difference between IVT-AFL T&E and RBZ T&E
in terms of improvement in visual acuity
(Fig. 2). All sensitivity analyses provided similar
conclusions.
Fig. 2 Difference between IVT-AFL T&E and RBZ T&E
in change in BCVA. BCVA best-corrected visual acuity,
Clr credibility intervals, IVT-AFL intravitreally adminis-
tered aflibercept, MAIC matching-adjusted indirect com-
parison, M1–2 main analyses 1 and 2, RBZ ranibizumab,
S1–S4C sensitivity analyses 1–4C, T&E treat-and-extend
regimen, 2-wk adj treatment interval adjusted every
2 weeks, 2-wk adj & 4-wk adj treatment interval adjusted
either every 2 or 4 weeks
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Results of Indirect Treatment Comparison
of Number of Injections
The mean number of injections received by
patients treated with IVT-AFL Q8W/PRN and
IVT-AFL T&E at week 96 was 11.2 and 10.4. The
median differences (95% CrI) in the number of
injections between IVT-AFL Q8W/PRN and IVT-
AFL T&E were 0.89 (0.35, 1.43) injections for
IPD meta-regression adjusted for the baseline
BCVA and age (M1) and 0.70 (0.15, 1.26)
injections for MAIC of IPD patients receiving
IVT-AFL T&E to aggregated IVT-AFL Q8W/PRN
with the baseline BCVA, age, and estimated
prevalence of PCV as covariates (M2).
The results of all sensitivity analyses were
consistent with M1 and M2 scenarios and
demonstrated that the IVT-AFL T&E regimen
was associated with 0.7–1.0 fewer injections on
average compared with IVT-AFL Q8W/PRN at
2 years.
The NMA pooling results of the network of
RCTs together with estimated difference
between regimens assessed in the ALTAIR and
VIEW studies demonstrated that at 2 years, IVT-
AFL T&E was associated with significantly fewer
injections compared with RBZ T&E, which was
confirmed across all sensitivity analyses
including direct comparison using MAIC
between IVT-AFL T&E and RBZ T&E. The mag-
nitude of the difference between IVT-AFL T&E
and RBZ T&E was approximately 6 injections in
both main scenarios and reached 7.5 injections
in the MAIC directly comparing IVT-AFL T&E
and RBZ T&E (Fig. 3).
DISCUSSION
This analysis was performed to fill gaps in clin-
ical evidence from RCTs on visual outcomes and
treatment burden of anti-VEGF T&E therapies
in a 2-year perspective. The NMA was performed
using six RCTs (ALTAIR, VIEW 1 and 2, CATT,
CANTREAT, and TREX). The results of this
comparison indicate that over 2 years, IVT-AFL
T&E provided visual improvements comparable
to those achieved with RBZ T&E with a lower
Fig. 3 Difference between IVT-AFL T&E and RBZ T&E
in change in number of injections. Clr credibility intervals,
IVT-AFL intravitreally administered aflibercept, MAIC
matching-adjusted indirect comparison, M1–2 main
analyses 1 and 2, RBZ ranibizumab, S1–S4C sensitivity
analyses 1–4C, T&E treat-and-extend regimen, 2-wk adj
treatment interval adjusted every 2 weeks, 2-wk adj & 4-wk
adj treatment interval adjusted either every 2 or 4 weeks
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treatment burden based on significantly fewer
injections.
The pivotal ALTAIR trial assessing two dif-
ferent regimens of IVT-AFL T&E regimens could
not be connected within a network of evidence
with the remaining trials assessing anti-VEGF
regimen, which precluded the possibility of
using standard network meta-analysis to com-
pare between IVT-AFL T&E and RBZ T&E.
Therefore, we followed the guidelines issued by
the NICE Decision Support Unit describing
methods for the population-adjusted indirect
comparison between disconnected evidence
and incomplete networks [23]. In this analysis
we conducted MAIC and adopted regression-
based analysis to reconstitute the connection of
incomplete networks of evidence allowing one
to compare between IVT-AF T&E versus RBZ
T&E.
Clinical data comparing the efficacy and
treatment burden of IVT-AFL and RBZ in a
longer perspective are limited. Results of an
NMA reported by Danyliv et al. did not
demonstrate significant differences between
IVT-AFL fixed regimens versus various RBZ reg-
imens regarding visual outcomes [30]. The esti-
mates presented by Danyliv et al. were based on
the two large RCTs (VIEW 1 and 2) designed to
compare IVT-AFL versus RBZ [27, 31]. During
the first year, patients received intravitreal
injections of RBZ every 4 weeks or IVT-AFL
every 4 weeks or every 8 weeks after three initial
monthly injections. During the second year,
patients continued to receive their originally
assigned agents. While patients were followed
up every 4 weeks and could receive injections at
follow-up visits, based on protocol-defined
retreatment criteria, only quarterly injections
were mandatory. The results of VIEW trials
indicate that IVT-AFL 2 mg monthly and RBZ
0.5 mg monthly were equally effective and had
comparable safety profiles at 1 year and 2 years,
despite that approximately five fewer doses were
administered in the 2 mg monthly IVT-AFL
group throughout the entire follow-up (16.0 vs
11.2 injections) [27, 31].
Although the VIEW trials demonstrate that
IVT-AFL yields visual effects similar to those
seen with RBZ, with a lower number of injec-
tions, it was not immediately understood how
those findings could be extrapolated to T&E
regimens [27]. While the RIVAL study is the
only clinical trial comparing IVT-AFL and RBZ
in an identical proactive treatment regimen,
described as T&E, the treatment criteria were
geared towards aggressive elimination of any
retinal fluid in order to achieve its primary
endpoint. This study had been designed to
assess treatment differences regarding the
change in the area of geographic atrophy from
baseline to 24 months as the primary outcome
measures. Visual outcomes and the number of
injections at 12 and 24 months were defined as
secondary objectives. Since the statistical anal-
ysis did not adjust for multiple comparisons,
the reported estimates should be interpreted
with caution. The recently published results
from the RIVAL study reported similar mean
BCVA gain in IVT-AFL and RBZ groups at
12 months (? 5.2 vs ? 6.9 logMAR letters) and
24 months (? 5.3 vs ? 6.5 logMAR letters)
[17, 18]. In the first year, patients received on
average 9.7 injections in each group, while over
entire 2-year treatment period the mean num-
ber of injections was 17.0 and 17.7 in IVT-AFL
and RBZ arms, respectively. The external valid-
ity of these estimates is questionable not only
because of the study design limitation related to
primary outcome and statistical analysis but
also owing to concerns regarding assessed
treatment regimens. All patients received allo-
cated therapies according to the same regimen
of three initial monthly doses followed by an
extension phase, during which the interval
between subsequent injections was adjusted by
2 weeks within a range of a minimum of
4 weeks and a maximum of 12 weeks between
administrations. Additionally, the between-
treatment interval was shortened to 4 weeks if
more than one sign of disease activity was
observed, thus limiting the number of possible
extensions. The schedule adopted in RIVAL
required more frequent IVT-AFL administration
compared with the European label for IVT-AFL,
which indicates that—after the 3 initial
monthly injections, the interval between sub-
sequent IVT-AFL injections should not be
shorter than 8 weeks. As a result, patients trea-
ted with IVT AFL in the RIVAL study received
more intensive treatment than has been
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described in the ALTAIR trial assessing IVT-AFL
regimens (17 injections vs 10.4 injections at 104
and 96 weeks, respectively) and combined IVT-
AFL Q8W arms from the VIEW 1 and 2 trials (17
injections vs 11.2 injections at 104 and
96 weeks, respectively), which may constitute
overtreatment. Importantly, the pooled results
of the VIEW 1 and 2 trials indicate that addi-
tional injections with IVT-AFL do not yield
additional clinical benefit [17]. Therefore an
injection of IVT-AFL when not clinically indi-
cated might not improve its efficacy compared
with RBZ T&E but potentially jeopardized the
between-treatment comparison regarding the
mean number of injections. A more intensive
intravitreal regimen may be considered justified
to treat patients with suboptimal response dur-
ing the treatment. For example, the presence of
PCV has been considered as a potential predic-
tor of poor response of patients with wAMD
treated with anti-VEGF regimens [32–34].
Approved IVT-AFL T&E regimen may not be
sufficient to treat non-responders with PCV,
who may require more frequent anti-VEGF
injections and the use of rescue photodynamic
therapy. As demonstrated in the PLANET trial,
around 12.1% of participants with PCV required
monthly IVT-AFL T&E combined with rescue
photodynamic therapy within the first year of
treatment [35]. Taking into account that the
RIVAL trial recruited predominantly white
patients with low baseline risk of PCV, it seems
unlikely that more intensive administration of
IVT-AFL T&E could be attributed to PCV-related
non-responders. Therefore, owing to the serious
methodological concerns and limited external
validity, the RIVAL trial was excluded from our
analysis.
The IVT-AFL T&E regimen has been granted
market authorization in the EU, Australia, and
Japan on the basis of the outcomes of the
ALTAIR study. This study demonstrated the
efficacy and treatment burden of two different
approaches of IVT-AFL T&E dosing with a
2-week and 4-week adjustment. At 2 years,
patients receiving IVT-AFL T&E improved their
visual acuity by 6.1–7.6 ETDRS letters with 10.4
injections compared with baseline. The evi-
dence from RCTs on the use of RBZ T&E at
2 years is also limited. Two ongoing studies met
the inclusion criteria for this analysis: the
CANTREAT trial and small TREX-AMD study. A
naive unadjusted comparison of the results
from these studies indicate that RBZ T&E pro-
vides visual improvement similar to that
achieved using IVT-AFL T&E (6.4 ETDRS letter
gain in CANTREAT and 8.7 in TREX), but with a
higher absolute number of injections (18.0 in
CANTREAT and 18.6 in TREX). These results are
consistent with the LUCAS trial, which was not
included in this analysis because it did not meet
the inclusion criteria (assessment of an off-label
therapy as comparator), in which at 2 years,
patients allocated to the RBZ T&E arm received
a mean number of 16.0 intravitreal injections,
which was associated with a 6.6 ETDRS letter
gain compared with baseline [36].
The current NMA has some limitations: first,
the connection between the ALTAIR study and
the network was reconstituted using methods
for an unanchored comparison, which allows
adjustments only for a few treatment modifiers
in each analysis. Second, standard deviations
were not published in all studies assessing RBZ
regimens and had to be imputed to conduct
NMA. Third, the proportion of patients with
PCV at baseline was available only for the
ALTAIR trial and had to be estimated for the
remaining trials in order to allow for PCV-ad-
justed analysis. The estimation of the percent-
age of patients with PCV was based on the
results of epidemiologic meta-analysis, includ-
ing 11 studies identified through SLR [29]. This
estimation is associated with inherent uncer-
tainty, since the prevalence of PCV in studies
included in this ITC could differ from the point
estimate reported in the meta-analysis.
Although there was a tentative estimation of
the proportion of PCV, populations enrolled in
different studies may vary. For these reasons,
the estimates adjusted for PCV should be
interpreted with caution. However, the sensi-
tivity analyses demonstrated that the adjust-
ment for baseline PCV may not change the
inference of this comparison. The results of all
the analyses consistently did not reveal any
significant differences between IVT-AFL T&E
and RBZ regarding visual acuity gain and
demonstrated a noticeably lower number of
injections in IVT-AFL T&E group. Models
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adjusting for baseline PCV slightly favored IVT-
AFL T&E in terms of visual acuity compared
with models not accounting for PCV although
without change of the inference. On the con-
trary, the estimates for the treatment burden
were highly consistent across all sensitivity
analyses with or without baseline PCV as a
covariate. This is because no interaction
between the presence of PCV and injection
frequency was observed in the ALTAIR trial.
Fourth, there was a slight discrepancy
between trials regarding the exact time point of
the data collection for the analysis at 2 years.
The data for the IVT-AFL T&E were collected
8 weeks earlier compared with the data for RBZ
T&E (96 weeks vs 104 weeks), which may
slightly interfere with the comparison between
IVT-AFL T&E and RBZ T&E regarding the num-
ber of injections. However, the impact of this
8-week difference is limited because of the low
frequency of IVT-AFL T&E administration in the
second year of the ALTAIR trial (3.7 injections
administered between week 54 and week 96).
On the basis of this information, it can be
assumed that patients would receive less than
one additional AFL injection if ALTAIR were
extended to 104 weeks. This means that at
104 weeks, IVT-AFL T&E is associated with an
estimated five fewer injections compared with
RBZ T&E. Finally, the included studies assessing
T&E regimens differed regarding the time when
the extension was initiated and the possible
ranges of injection intervals. It cannot be
excluded that the between-study differences
regarding T&E posology may, in part, explain
the difference in the number of injections
between IVT-AFL T&E and RBZ T&E estimated
in this analysis.
Administration of anti-VEGF therapy impo-
ses a serious burden on patients due to treat-
ment-related anxiety, financial considerations,
and transport burden [37]. Most patients with
wAMD have varying degrees of disability due to
age and insufficient vision, and thus require
help in their daily activities as well as escorts
when travelling to the hospital [38, 39]. The
disease itself and the treatment frequency are
therefore associated with a significant caregiver
burden, which can have a negative impact on
the relationships between the caregiver and
patient [38, 40]. The frequency of injections can
be considered a relevant surrogate of a treat-
ment burden. Therefore, the results of our
comparison indicate that IVT-AFL T&E may
serve as an optimal treatment option, owing to
its clinical efficacy, which is comparable to that
of RBZ T&E, and a noticeably lower treatment
burden [6].
The between-treatment difference in the
number of injections is consistent with indi-
vidual RCT results and reflects differences in the
T&E regimens tested and criteria for extension
adopted in respective studies. In the ALTAIR
trial, IVT-AFL T&E was administered at weeks 0,
4, 8, and 16, followed by the variable treatment
interval ranging from 8 to 16 weeks. The inter-
val was adjusted on the basis of physician
judgment of vision and/or anatomic outcomes.
On the contrary, RBZ T&E monthly treatment
could be continued following initial doses (1)
until (in the CANTREAT study) visual acuity was
deemed stable, indicated by an improvement in
visual acuity of at most 3 ETDRS letters gained
(or no loss of more than 5 letters) from the prior
month; no clinical evidence of lesion growth,
fluid, or blood; and no intraretinal or subretinal
fluid seen on optical coherence tomography; or
(2) until (in the TREX study) achievement of
‘‘dry’’ retina based on resolution of intraretinal
and subretinal fluid and all subretinal hemor-
rhage related to active wAMD. When this was
achieved, the treatment interval could be
extended by 2 weeks to a maximum of
12 weeks. In the case of recurrent disease activ-
ity, the between-injection interval could be
shortened to a minimum of 4 weeks.
Finally, this analysis was based on RCTs
conducted under experimental conditions with
tightly defined treatment algorithms, which
might not fully reflect the posology used in real
clinical practice. Therefore, the differences in
relative efficacy and treatment burden between
IVT-AFL T&E and RBZ T&E administered in the
real-world settings may potentially differ from
the estimates of this analysis.
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CONCLUSIONS
Patients with wAMD receiving an IVT-AFL T&E
regimen can achieve and maintain improve-
ment in visual acuity with fewer injections over
a 2-year period compared with those receiving
RBZ T&E. Because it is associated with clinical
efficacy and a minimized treatment burden,
IVT-AFL T&E may therefore serve as the optimal
therapy for wAMD.
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